Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Reply to: residual risk after familial RYR1 testing: interpreting malignant hyperthermia susceptibility in the context of regional testing strategies.

European journal of human genetics : EJHG·2026
Same author

Pathogenic variants in the autophagy-tethering factor EPG5 drive neurodegeneration through mitochondrial dysfunction and innate immune activation.

Nature communications·2026
Same author

EMQN Best Practice Guidelines for Genetic Testing and Reporting in RYR1-related disorders.

European journal of human genetics : EJHG·2026
Same author

Liver health in myotubular and centronuclear myopathies: a patient-driven data collection study to better understand liver health and improve standards of care.

Neuromuscular disorders : NMD·2026
Same author

A comprehensive framework for the interpretation of TTN missense variants.

Genome medicine·2026
Same author

Congenital myasthenic syndrome: is it time for a name change to genetic myasthenic syndrome?

Brain : a journal of neurology·2026
Same journal

Triple A syndrome with a new mutation pattern, first documented case in Austria: a case report with literature review.

Orphanet journal of rare diseases·2026
Same journal

Analysis of homocysteine levels in carriers with MMACHC gene variants.

Orphanet journal of rare diseases·2026
Same journal

Prevalence and cardiovascular phenotypes of dextrocardia and situs inversus among 277,396 adults: longitudinal evidence of amplified age-related blood pressure progression.

Orphanet journal of rare diseases·2026
Same journal

Automated quantification of skin Gb3 load and white matter lesion assessment in Fabry disease.

Orphanet journal of rare diseases·2026
Same journal

Elamipretide in pediatric Barth syndrome: from heart failure to school return.

Orphanet journal of rare diseases·2026
Same journal

Unraveling the psychological burden of Behçet disease: the impact of anxiety and depression on health-related quality of life outcomes.

Orphanet journal of rare diseases·2026
See all related articles

Related Experiment Video

Updated: Jan 14, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.0K

Multi-minicore Disease.

Heinz Jungbluth1

  • 1Department of Paediatric Neurology, Evelina Children's Hospital, St. Thomas' Hospital, London, UK. Heinz.Jungbluth@gstt.nhs.uk

Orphanet Journal of Rare Diseases
|July 17, 2007
PubMed
Summary
This summary is machine-generated.

Multi-minicore Disease (MmD) is a genetic neuromuscular disorder with varied symptoms. Diagnosis involves muscle biopsy and genetic testing, with management focusing on supportive care and potential complications.

More Related Videos

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.2K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.2K

Related Experiment Videos

Last Updated: Jan 14, 2026

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
08:51

Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts

Published on: September 20, 2024

2.0K
In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila
06:41

In Vivo Functional Study of Disease-associated Rare Human Variants Using Drosophila

Published on: August 20, 2019

14.2K
In Vivo Modeling of the Morbid Human Genome using Danio rerio
12:31

In Vivo Modeling of the Morbid Human Genome using Danio rerio

Published on: August 24, 2013

21.2K

Area of Science:

  • Neurology
  • Genetics
  • Muscle Biology

Background:

  • Multi-minicore Disease (MmD) is a rare, inherited neuromuscular disorder.
  • It is characterized by multiple cores observed in muscle biopsies, indicative of a congenital myopathy.
  • Clinical presentation shows significant variability, linked to underlying genetic causes.

Purpose of the Study:

  • To summarize the genetic heterogeneity, diagnostic approaches, and management strategies for Multi-minicore Disease.
  • To differentiate phenotypes associated with SEPN1 and RYR1 gene mutations.
  • To highlight diagnostic aids like muscle MRI and genetic testing.

Main Methods:

  • Review of clinical features, muscle biopsy findings (multiple cores), and genetic analysis.
  • Correlation of specific gene mutations (SEPN1, RYR1) with distinct clinical phenotypes.
  • Discussion of diagnostic tools including muscle MRI and genetic testing.

Main Results:

  • Recessive SEPN1 mutations typically cause a classic phenotype with spinal rigidity, scoliosis, and respiratory issues.
  • Recessive RYR1 mutations are linked to a broader spectrum of symptoms, including ophthalmoplegia and distal weakness, sometimes resembling Central Core Disease.
  • Muscle MRI patterns can differ based on the genetic background, aiding diagnosis.

Conclusions:

  • MmD diagnosis relies on clinical suspicion, muscle biopsy, and genetic confirmation via RYR1 or SEPN1 gene analysis.
  • Management is supportive, addressing respiratory risks (SEPN1) and malignant hyperthermia susceptibility (RYR1).
  • Prognosis is generally static or slowly progressive, with respiratory function being a key factor.